Fidelity Investments’s Viridian Therapeutics VRDN Stock Holding History

Fidelity Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305M	Buy	16,604,740 +1,225,363	+8%	+$19.7M	0.01%	751
2026 Q1	$301M	Buy	15,379,377 +994,921	+7%	+$29.5M	0.02%	690
2025 Q4	$448M	Buy	14,384,456 +2,135,101	+17%	+$58.6M	0.02%	554
2025 Q3	$264M	Buy	12,249,355 +10,552	+0.1%	+$190K	0.01%	738
2025 Q2	$171M	Buy	12,238,803 +15,817	+0.1%	+$215K	0.01%	885
2025 Q1	$165M	Buy	12,222,986 +341,074	+3%	+$5.81M	0.01%	881
2024 Q4	$228M	Buy	11,881,912 +698,434	+6%	+$15.2M	0.01%	767
2024 Q3	$254M	Buy	11,183,478 +1,610,130	+17%	+$26.3M	0.02%	738
2024 Q2	$125M	Buy	9,573,348 +158,213	+2%	+$2.19M	0.01%	969
2024 Q1	$165M	Buy	9,415,135 +1,789,593	+23%	+$34.7M	0.01%	867
2023 Q4	$166M	Buy	7,625,542 +7,363,354	+2,808%	+$116M	0.01%	821
2023 Q3	$4.02M	Buy	262,188 +429	+0.2%	+$8.18K	﹤0.01%	2106
2023 Q2	$6.23M	Buy	261,759 +117,611	+82%	+$3.02M	﹤0.01%	2001
2023 Q1	$3.67M	Buy	144,148 +142,950	+11,932%	+$4.58M	﹤0.01%	2188
2022 Q4	$35K	Buy	1,198 +755	+170%	+$17.4K	﹤0.01%	3563
2022 Q3	$9K	Buy	443 +374	+542%	+$6.72K	﹤0.01%	4132
2022 Q2	$1K	Buy	+69	New	+$927	﹤0.01%	4817
2020 Q4	–	Sell	-259,244	Closed	-$3.01M	–	4321
2020 Q3	$3.01M	Hold	259,244	–	–	﹤0.01%	2205
2020 Q2	$4.32M	Hold	259,244	–	–	﹤0.01%	2095
2020 Q1	$1.74M	Buy	259,244 +66,667	+35%	+$776K	﹤0.01%	2226
2019 Q4	$1.39M	Hold	192,577	–	–	﹤0.01%	2346
2019 Q3	$2.11M	Hold	192,577	–	–	﹤0.01%	2257
2019 Q2	$5.92M	Hold	192,577	–	–	﹤0.01%	2045
2019 Q1	$8.06M	Hold	192,577	–	–	﹤0.01%	1937
2018 Q4	$8.75M	Sell	192,577 -63,295	-25%	-$3.66M	﹤0.01%	1846
2018 Q3	$21.4M	Sell	255,872 -32,987	-11%	-$3.11M	﹤0.01%	1651
2018 Q2	$27.8M	Hold	288,859	–	–	﹤0.01%	1556
2018 Q1	$30.4M	Buy	288,859 +80,533	+39%	+$8.75M	﹤0.01%	1524
2017 Q4	$32.6M	Hold	208,326	–	–	﹤0.01%	1492
2017 Q3	$28.6M	Hold	208,326	–	–	﹤0.01%	1561
2017 Q2	$40.4M	Hold	208,326	–	–	0.01%	1378
2017 Q1	$38.9M	Buy	+208,326	New	+$35.9M	﹤0.01%	1440

Other funds holding VRDN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments's VRDN Position: Q2 2026 in Review

Fidelity Investments increased its Viridian Therapeutics (VRDN) stake by 8% in Q2 2026, buying an estimated $19.7M and bringing the position to 16,604,740 shares worth $305M. The position accounts for 0.01% of the portfolio, ranked #751.

Fidelity Investments first reported a position in VRDN in Q1 2017 and has held it in 32 quarters since. The position peaked at $448M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Fidelity Investments held 16,604,740 shares of Viridian Therapeutics worth $305M as of Q2 2026.
Fidelity Investments bought 1,225,363 Viridian Therapeutics shares in Q2 2026, an estimated $19.7M.
Viridian Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #751 holding.
Fidelity Investments first reported a position in Viridian Therapeutics in Q1 2017 and has held it in 32 quarters since.
Fidelity Investments's Viridian Therapeutics position peaked at $448M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.